Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?

Παρόμοια τεκμήρια

• Conflicts cause FDA to review advisory committees
  ανά: Kondro, Wayne
  Έκδοση: (2006)
• FDA to clarify rules on advisory committee members
  ανά: Tanne, Janice Hopkins
  Έκδοση: (2006)
• Revisiting Financial Conflicts of Interest in FDA Advisory Committees
  ανά: Pham-Kanter, Genevieve
  Έκδοση: (2014)
• FDA Advisory Committee Meeting on Prasugrel For Acute Coronary Syndromes
  ανά: Alexander, Walter
  Έκδοση: (2009)
• Compensation, Productivity, and Other Demographics of Academic Divisions of Endocrinology, Diabetes, and Metabolism
  ανά: Ringel, Matthew D, κ.ά.
  Έκδοση: (2019)